Ke Li

Ke Li


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2025 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
PDF file
SLShuang Li
Shuang Li
LYLili Yang
Lili Yang
XFXiaoyan Feng
Xiaoyan Feng
XPXi Peng
Xi Peng
JZJunmei Zhang
Junmei Zhang
KLKe Li
Ke Li
Purpose Although candidemia has been reported globally, little is known about the differences in candidemia episodes between ICU and regular wards or the correlation between serum biomarkers and mortality from candidemia in medium and small cities. Patients and methods We conducted a retrospective study of the risk factors and clinical outcomes of hospitalized patients with candidemia from 2021 to 2024 in southwest China. A multivariate logistic regression model was performed to investigate several potential risk factors for mortality. Results We collected 152 non-duplicate candidemia isolates during the study period. Candida albicans was the leading species causing candidemia (33.6%), and 96.7% of these isolates were susceptible to amphotericin B. Compared with regular patients, patients admitted to ICU were more frequently subjected to severe clinical presentations, extensive invasive procedures, and heavy exposure to antibiotics. In addition, the mortality in ICU was significantly higher than that in regular wards. Multivariable analysis revealed that 30-day readmission, mechanical ventilation, and ICU admission were independent factors associated with 30-day mortality. Moreover, we observed that high levels of PCT, BDG, and IL-6, as well as low PLT counts were also associated with mortality from candidemia. Conclusions A better understanding of the specific risk factors across ICU wards could facilitate the identification of high-risk candidates for early antifungal therapy, thereby improving the outcomes for critically ill patients with candidemia.

13 February 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
SLShuang Li
Shuang Li
LYLili Yang
Lili Yang
YGYuanbiao Guo
Yuanbiao Guo
XFXiaoyan Feng
Xiaoyan Feng
LYLing Ye
Ling Ye
KLKe Li
Ke Li
Mycoplasma hominis is a part of the microflora of the urogenital tract; however, extra-urogenital infections due to M. hominis are rare. Herein, we present a case study of a patient who successfully recovered from a sternal wound infection caused by M. hominis. We report a case of sternal wound infection caused by M. hominis following tricuspid valvuloplasty. The patient developed a severe infection despite postoperative antimicrobial therapy. Wound sample cultures grew pinpoint-sized colonies on blood agar plates, which were identified as M. hominis by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). Based on the results of the antibiotic susceptibility test, effective infection management was achieved using a combination of moxifloxacin and doxycycline. The potential role of M. hominis as a causative agent of postoperative infections after thoracotomy may be underestimated. M. hominis should be highly suspected when patients have an indwelling catheter or when perioperative wound samples show numerous leukocytes with no visible bacteria, and are unresponsive to standard empirical treatment for postoperative infections.

13 October 2026 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
LFLingYi Feng
LingYi Feng
YXYuPei Xia
YuPei Xia
QXQianRong Xie
QianRong Xie
YWYuJing Wang
YuJing Wang
KLKe Li
Ke Li
Background: The triglyceride-glucose (TyG) index is associated with hyperuricemia, but the longitudinal interpretation of within-person change is complicated when repeated exposure measurements overlap with outcome ascertainment. We examined whether one-year change in the TyG index was associated with subsequent incident hyperuricemia among adults undergoing repeated annual health examinations. Methods: We conducted a retrospective landmark cohort study using annual health-examination data from 2023 to 2025 at a tertiary hospital in China. Adults had to remain normouricemic through the 2024 landmark. The prespecified primary analysis evaluated 2023–2024 TyG change in a joint model with baseline TyG, age, sex, and the most recent pre-outcome serum urate and estimated glomerular filtration rate (eGFR) values from 2024. A complementary baseline-covariate model used 2023 serum urate and eGFR. Modified Poisson regression with robust variance estimated risk ratios (RRs) and 95% confidence intervals (CIs). Results: Among 21,188 participants, 1,171 (5.5%) developed hyperuricemia in 2025. In the prespecified primary model, a 1-standard-deviation (SD) greater one-year TyG change was associated with incident hyperuricemia after adjustment for baseline TyG, age, sex, 2024 eGFR and 2024 serum urate (RR 1.120, 95% CI 1.061–1.181). The complementary baseline-covariate model using 2023 eGFR and serum urate gave a similar estimate (RR 1.139, 95% CI 1.080–1.201). Adding one-year TyG change increased the apparent C-statistic only slightly, from 0.801 to 0.803. Conclusions: In this repeated health-examination cohort, greater one-year TyG change was associated with subsequent incident hyperuricemia after accounting for baseline TyG and the most recent pre-outcome urate and renal-function values. The incremental gain in discrimination was very small, and the findings should be interpreted as observational associations rather than evidence of clinical predictive utility or causality.

2 September 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DPDan Peng
Dan Peng
XFXiaoyan Feng
Xiaoyan Feng
HZHang Zhang
Hang Zhang
PYPeng Yue
Peng Yue
JZJunmei Zhang
Junmei Zhang
KLKe Li
Ke Li
Although gut microbiota metabolites (GMMs) show therapeutic activity against Klebsiella pneumoniae pneumonia (KPP), their underlying mechanisms remain unclear. Therefore, identifying biomarkers associated with the therapeutic effects of GMM on KPP is crucial. Targets associated with gut microbiota (GM), GMM, and KPP were collected from several databases. Intersecting targets were considered candidate biomarkers and subject to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment and subcellular localization analyses. Key metabolites were screened based on drug-likeness and toxicity. Molecular docking and dynamics simulations were conducted to evaluate metabolite–biomarker interactions. Furthermore, database predictions yielded 117 GM targets, 686 GMM targets, and 226 KPP targets. Five overlapping targets (IL6, NFKB1, PTGER3, PPARG, and TLR4) were selected as candidate biomarkers. KEGG analysis revealed 67 enriched pathways, including toll-like receptor signaling. Subcellular localization predicted IL6 (extracellular matrix), NFKB1, PPARG (nucleus), PTGER3 and TLR4 (plasma membrane). Ethyl phenyllactate(-)-, 5-(3-hydroxyphenyl) pentanoic acid, and glycocholic acid were identified as key metabolites. Moreover, molecular docking predicted stable binding for all metabolite–biomarker pairs, and molecular dynamics simulations suggested that the ethyl phenyllactate(-)-–NFKB1 complex had the highest conformational stability among the tested complexes. Clinical validation using two independent transcriptomic datasets (GSE33341 and GSE60244) of gram-negative bacterial infections confirmed that NFKB1, PPARG, and TLR4 were substantially upregulated, and a five-biomarker combined model achieved high diagnostic accuracy (area under the curve = 0.885–0.982). We identified IL6, NFKB1, PTGER3, PPARG, and TLR4 as potential biomarkers for GMM-based treatment of KPP. Ethyl phenyllactate(-)- is considered a key metabolite that interacts stably with NFKB1. These results offer potential mechanistic insight into the regulatory role of GMM in KPP therapy.

19 September 2026 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
LFLingYi Feng
LingYi Feng
QXQianRong Xie
QianRong Xie
YWYuJing Wang
YuJing Wang
KLKe Li
Ke Li
In intensive-care-unit (ICU) sepsis, C-reactive protein (CRP), procalcitonin (PCT), the white-cell count (WBC) and neutrophil-to-lymphocyte ratio (NLR) are

20 May 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
NPNingjing Pu
Ningjing Pu
JXJuan Xiong
Juan Xiong
YSYueshan Sun
Yueshan Sun
KLKe Li
Ke Li
YGYuanbiao Guo
Yuanbiao Guo
Objective: Our objective was to investigate the association between serum phosphorus levels and 28-day mortality in patients with bloodstream infection (BSI), and to explore whether this association persists after adjusting for renal function and clinical severity. Methods: This retrospective cohort study included 214 BSI patients. Patients were divided into hyperphosphatemia (≥2.2 mmol/L, n = 15) and control (<2.2 mmol/L, n = 199) groups. To address the small sample size and potential separation, multivariate Firth’s penalized likelihood regression was utilized to evaluate the association with 28-day mortality. Restricted cubic spline regression explored the continuous relationship. Fine–Gray competing risk models, 1000-resample bootstrapping, and E-value analyses were conducted to ensure the robustness of the observed associations. Results: The 28-day mortality rate was significantly higher in the hyperphosphatemia group (80.0% vs. 39.7%, p = 0.005). After adjusting for age, sex, and estimated glomerular filtration rate (eGFR), hyperphosphatemia remained significantly associated with higher observed 28-day mortality (OR = 4.46, 95% CI: 1.36–18.54, p = 0.012). This association remained robust even after further adjustment for septic shock (OR = 4.74, 95% CI: 1.30–21.64, p = 0.017). Analyzed continuously, each 0.5 mmol/L increase in serum phosphorus was associated with 34% higher odds of mortality (OR = 1.34, 95% CI: 1.07–1.74, p = 0.01). Spline analysis confirmed a nonlinear relationship with a threshold at 2.2 mmol/L. Kaplan–Meier analysis demonstrated a severity-driven survival separation in the hyperphosphatemia group (Log-rank p < 0.001). The association remained highly robust after adjusting for early discharge competing risks (sHR = 4.62, p < 0.001) and in bootstrap validation (median OR = 4.80). Conclusions: Serum phosphorus ≥ 2.2 mmol/L is associated with higher observed mortality in BSI patients, an association that remained evident after adjusting for renal function and clinical severity, including septic shock. However, given the small hyperphosphatemia subgroup (n = 15), limited statistical stability, and the potential for residual confounding, these findings should be considered hypothesis-generating rather than definitive, requiring prospective validation in larger, adequately powered cohorts. Rather than a definitive triage tool, serum phosphorus may serve as a simple, adjunctive marker for early metabolic assessment in severe infections.